Posted by Michael Wonder on 15 Jul 2025
Health Canada extends the approval of Evkeeza (evinacumab) to children as young as 6 months old with homozygous familial hypercholesterolaemia
14 July 2025 - Ultragenyx today announced that Health Canada has extended the approval of Evkeeza (evinacumab) as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies to treat children aged 6 months and older with homozygous familial hypercholesterolaemia.
Evkeeza, an angiopoietin-like 3 inhibitor initially received Health Canada approval in September 2023 as an adjunct to diet and other LDL-cholesterol lowering therapies for the treatment of adult and paediatric patients aged 5 years and older with homozygous familial hypercholesterolaemia, a disease associated with dangerously high levels of LDL-cholesterol.
